00:25:18 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-28 Halvårsrapport
2024-03-25 X-dag ordinarie utdelning FARON 0.00 EUR
2024-03-22 Årsstämma
2024-03-14 Bokslutskommuniké 2023
2023-08-29 Halvårsrapport
2023-03-27 X-dag ordinarie utdelning FARON 0.00 EUR
2023-03-24 Årsstämma
2023-03-03 Bokslutskommuniké 2022
2022-08-25 Halvårsrapport
2022-07-07 Extra Bolagsstämma 2022
2022-04-25 X-dag ordinarie utdelning FARON 0.00 EUR
2022-04-22 Årsstämma
2022-03-25 Bokslutskommuniké 2021
2021-08-26 Halvårsrapport
2021-04-26 X-dag ordinarie utdelning FARON 0.00 EUR
2021-04-23 Årsstämma
2021-03-25 Bokslutskommuniké 2020
2020-05-14 X-dag ordinarie utdelning FARON 0.00 EUR
2020-05-13 Årsstämma
2020-03-20 Bokslutskommuniké 2019

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriBioteknik
Faron Pharmaceuticals är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling av terapeutiska lösningar som används för behandling av immuna sjukdomar och diverse organskador. Störst verksamhet återfinns inom Nordamerika samt Europa, med sjukhus och forskningsinstitut som dominerande kundbas. Utöver huvudverksamheten erbjuds diverse mervärdestjänster. Huvudkontoret ligger i Turku.
2023-09-06 08:00:00

Faron Pharmaceuticals Ltd. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

TURKU, Finland / BOSTON, Massachusetts - September 6, 2023 - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that Dr Markku Jalkanen, PhD, CEO will present at the H.C. Wainwright Annual Global Investment Conference in New York City on September 12, 2023.  In addition to the presentation, company management will be available for one-on-one meetings with investors.

H.C. Wainwright Global Investment Conference

Date: Tuesday, September 12, 2023

Time: 10:30 a.m. ET

Location: Room Holmes I, 4th floor

Format: Company Presentation

For more information please contact:

Investor Contact

LifeSci Advisors

Daniel Ferry

Managing Director

daniel@lifesciadvisors.com

+1 (617) 430-7576

Media Contact

Faron Pharmaceuticals

Jennifer C. Smith-Parker

Head of Communications

Jennifer.Smith-Parker@faron.com

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tacklingcancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com (https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.faron.com%2F&data=05%7C01%7C%7Ca4ae0afa96854c5c5f2a08db771ae20d%7Ca2d9b7a432f64a96b03727499230d5fd%7C1%7C0%7C638234729855975666%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=%2FNadoN9wXIGZtfCkFVuLSTXPpNg3%2BBXoRfIQaIPce6k%3D&reserved=0).